It was a nice end to the week. I suspect that we should have a little follow up but we are probably due for a pause sooner rather than later. Although it might not feel like it but we are up 20%+ from the recent lows. I am sure we all feel that the sector […]
December 1st Biotech Update
We the news that we needed to really push the sector higher with a large oncology deal. Now the move is good to see and certainly adds some nice momentum to the sector but ideally we would want that to last a couple of days. One day spike higher and then giving it back over […]
November 29th Biotech Update
Not the greatest start to the week but also not the worst. No significant green bars but we also seem to have hit some area of support each day and rallied. As long as that trend is maintained this is not a bad situation. One could be looking at the development of support at these […]
November 27th Biotech Update
There is really not a lot to talk about. The news coming out of the holiday is pretty slow. I will keep this short as we continue to setup the end of the year. It will be interesting to see what happens with the competing pressure in the sector with some tailwinds as rates seem […]
Mailing List
Introduction
Overview
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.
